These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32807691)

  • 1. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease.
    Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A;
    Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.
    Peyrin-Biroulet L; Lönnfors S; Roblin X; Danese S; Avedano L
    J Crohns Colitis; 2017 Jan; 11(1):128-133. PubMed ID: 27481878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians.
    Park SK; Moon W; Kim ES; Park SH; Park DI
    Korean J Gastroenterol; 2019 Dec; 74(6):333-340. PubMed ID: 31870139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
    Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in inflammatory bowel disease.
    Talathi S; Baig KRKK
    J Dig Dis; 2020 Nov; 21(11):610-620. PubMed ID: 32920972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease.
    Macaluso FS; Mazzola G; Ventimiglia M; Alvisi P; Renna S; Adamoli L; Galli M; Armuzzi A; Ardizzone S; Cascio A; Cottone M; Orlando A;
    Digestion; 2020; 101(4):433-440. PubMed ID: 31167191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2014 Nov; 8(11):1548-50. PubMed ID: 25008477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.
    Peyrin-Biroulet L; Lönnfors S; Avedano L; Danese S
    United European Gastroenterol J; 2019 Dec; 7(10):1345-1352. PubMed ID: 31839960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group.
    Dipasquale V; Martinelli M; Aloi M; Accomando S; Alvisi P; Arrigo S; Banzato C; Bramuzzo M; Cananzi M; Corpino M; Di Mari C; Di Nardo G; Dilillo A; Dodaro N; Felici E; Gatti S; Graziano F; Illiceto MT; Norsa L; Opramolla A; Pastore M; Pavanello PM; Romeo E; Scarallo L; Strisciuglio C; Zuin G; Romano C
    Paediatr Drugs; 2022 Jan; 24(1):57-62. PubMed ID: 34914084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
    Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL
    Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
    Annese V; Vecchi M;
    Dig Liver Dis; 2014 Nov; 46(11):963-8. PubMed ID: 25139379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD).
    Viscido A; Buda A; Caprioli F; Principi M; Daperno M; Armuzzi A
    Dig Liver Dis; 2020 Aug; 52(8):928-930. PubMed ID: 32616462
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
    Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.